The role of histone protein modifications and mutations in histone modifiers in pediatric b-cell progenitor acute lymphoblastic leukemia
Paige, Adam J.W.
MetadataShow full item record
AbstractWhile cancer has been long recognized as a disease of the genome, the importance of epigenetic mechanisms in neoplasia was acknowledged more recently. The most active epigenetic marks are DNA methylation and histone protein modifications and they are involved in basic biological phenomena in every cell. Their role in tumorigenesis is stressed by recent unbiased large-scale studies providing evidence that several epigenetic modifiers are recurrently mutated or frequently dysregulated in multiple cancers. The interest in epigenetic marks is especially due to the fact that they are potentially reversible and thus druggable. In B-cell progenitor acute lymphoblastic leukemia (BCP-ALL) there is a relative paucity of reports on the role of histone protein modifications (acetylation, methylation, phosphorylation) as compared to acute myeloid leukemia, T-cell ALL, or other hematologic cancers, and in this setting chromatin modifications are relatively less well studied and reviewed than DNA methylation. In this paper, we discuss the biomarker associations and evidence for a driver role of dysregulated global and loci-specific histone marks, as well as mutations in epigenetic modifiers in BCP-ALL. Examples of chromatin modifiers recurrently mutated/disrupted in BCP-ALL and associated with disease outcomes include MLL1, CREBBP, NSD2, and SETD2. Altered histone marks and histone modifiers and readers may play a particular role in disease chemoresistance and relapse. We also suggest that epigenetic regulation of B-cell differentiation may have parallel roles in leukemogenesis.
CitationJanczar S, Janczar K, Pastorczak A, Harb H, Paige AJW, Zalewska-Szewczyk B, Danilewicz M, Mlynarski W (2017) 'The role of histone protein modifications and mutations in histone modifiers in pediatric b-cell progenitor acute lymphoblastic leukemia', Cancers, 9 (1), pp.2-.
PubMed Central IDPMC5295773
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Green - can archive pre-print and post-print or publisher's version/PDF
- Preserved global histone H4 acetylation linked to ETV6-RUNX1 fusion and PAX5 deletions is associated with favorable outcome in pediatric B-cell progenitor acute lymphoblastic leukemia.
- Authors: Janczar K, Janczar S, Pastorczak A, Mycko K, Paige AJ, Zalewska-Szewczyk B, Wagrowska-Danilewicz M, Danilewicz M, Mlynarski W
- Issue date: 2015 Dec
- Chromatin modifiers and histone modifications in bone formation, regeneration, and therapeutic intervention for bone-related disease.
- Authors: Gordon JAR, Stein JL, Westendorf JJ, van Wijnen AJ
- Issue date: 2015 Dec
- The re-expression of the epigenetically silenced e-cadherin gene by a polyamine analogue lysine-specific demethylase-1 (LSD1) inhibitor in human acute myeloid leukemia cell lines.
- Authors: Murray-Stewart T, Woster PM, Casero RA Jr
- Issue date: 2014 Mar
- Insights into novel emerging epigenetic drugs in myeloid malignancies.
- Authors: Chandhok NS, Prebet T
- Issue date: 2019
- Epigenetic alterations in hematopoietic malignancies.
- Authors: Chung YR, Schatoff E, Abdel-Wahab O
- Issue date: 2012 Oct